, which is generated through the oxidation of 5-methylcytosine by the TET enzyme family. Here we show that 5hmC levels increase significantly during reprogramming to human iPSCs mainly owing to TET1 activation, and this hydroxymethylation change is critical for optimal epigenetic reprogramming, but does not compromise primed pluripotency. Compared with hESCs, we find that iPSCs tend to form large-scale (100 kb-1.3 Mb) aberrant reprogramming hotspots in subtelomeric regions, most of which exhibit incomplete hydroxymethylation on CG sites. Strikingly, these 5hmC aberrant hotspots largely coincide (∼80%) with aberrant iPSC-ESC non-CG methylation regions. Our results suggest that TET1-mediated 5hmC modification could contribute to the epigenetic variation of iPSCs and iPSC-hESC differences.
is abundant in the central nervous system and ESCs. Several reports have explored the genome-wide distribution of 5hmC modification in mouse ESCs and hESCs, and suggest that it is enriched in gene bodies and enhancers 13, 14 . Reprogramming towards pluripotency involves a dynamic epigenetic modification process. 5hmC has been implicated in the DNA demethylation process 15 , pointing to a potential role for 5hmC modification during reprogramming towards pluripotency. Thus, understanding the dynamic 5hmC changes during reprogramming will provide further insight into somatic cell reprogramming mechanisms.
Multiple studies suggest that there are subtle yet substantial genetic and epigenetic differences between iPSCs and hESCs (refs 16,17) . The present consensus is that iPSCs and ESCs are two overlapping classes of heterogeneous cells, with iPSCs being more variable than hESCs (ref. 18) . Although iPSCs and hESCs are functionally equivalent in general, the subtle genetic and epigenetic differences could lead to functional consequences among individual lines. Previous studies of the base-resolution methylomes of iPSCs and ESCs identified differentially methylated regions (DMRs) between iPSCs and ESCs, consisting of CG-DMRs and non-CG-DMRs (refs 16,17) . However, the traditional bisulphite sequencing technique they used could not distinguish 5mC from 5hmC (ref. 19) , which means that how these DMRs are caused by hydroxymethylation differences remains unknown.
Here we show that 5hmC levels increase significantly during reprogramming to human iPSCs mainly owing to TET1 activation, and this hydroxymethylation change is critical for optimal epigenetic reprogramming. We found that during reprogramming extensive genome-wide 5hmC modification occurs. Importantly, we identified specific aberrant reprogramming hotspots in iPSCs, which cluster on a large scale (100 kb-1.3 Mb) at subtelomeric regions bearing incomplete CG hydroxymethylation. These hotspots largely overlap with aberrant non-CG methylation hotspots, suggesting that hydroxymethylation contributes to the epigenetic difference between iPSCs and hESCs.
RESULTS

TET1-mediated hydroxymethylation plays a critical role during reprogramming to pluripotency in human cells
DNA methylation is a major barrier to iPSC reprogramming. Several lines of evidence suggest that 5hmC is involved in the process of DNA demethylation 20, 21 . We found a significant increase of the 5hmC level in human iPSCs when compared with their original fibroblasts, with the amount in iPSCs being similar to that in hESCs (Fig. 1a) .
TET family proteins (TET1, TET2 and TET3) could convert 5mC to 5hmC (ref. 6 ). We found a statistically significant increase in the level of TET1 and TET3; with a more pronounced increase of TET1, and a slight decrease of TET2 expression (Fig. 1b) . RNA-seq reveals that TET1 is at a comparable level to NANOG in pluripotent cells, but the expression levels of TET2 and TET3 are significantly lower (Fig. 1c) . Depletion of TET1 but not TET2 and TET3 by short interfering RNA (siRNA) could significantly decrease total 5hmC levels in human iPSCs ( Fig. 1d and Supplementary Fig. S1a,b) . Therefore, we conclude that TET1 is the main TET protein regulating hydroxymethylation during human iPSCs reprogramming.
As cellular reprogramming is an epigenetic-state reconfiguring process, we next examined whether TET1-mediated hydroxymethylation changes are critical in human iPSC reprogramming. Introducing TET1 short hairpin RNA (shRNA) lentivirus with Yamanaka factors decreased the number of colonies positive for alkaline phosphatase when compared with equal-titre control shRNA lentivirus transduction (Fig. 1e,f and Supplementary Fig. S1c,d ). Colonies treated with TET1-shRNA during reprogramming can be further stably maintained, showing decreased TET1 expression levels, but similar pluripotent gene expression levels when compared to iPSCs (Fig. 1g) . Furthermore, iPSCs depleted with TET1 maintained a normal undifferentiated stem cell morphology, were positive for alkaline phosphatase, expressed the same level of pluripotent-related factors and stained positive for pluripotency markers such as NANOG, SOX2 and TRA-1-81 ( Fig. 1h and Supplementary Fig. S1e-g ). Therefore, TET1-mediated hydroxymethylation modification is required for optimal induction of iPSCs, but does not compromise the essential pluripotency of human stem cells.
5hmC epigenomic landscape during reprogramming
We employed 5hmC Capture-seq to assess genome-wide 5hmC distributions during reprogramming 11 . The cell lines and sequencing statistics are summarized in Supplementary Tables S2 and S3 . Pearson correlation and cluster analysis of the global 5hmC modification pattern suggests a significant difference between iPSCs and fibroblasts ( Fig. 2a and Supplementary Table S4) .
On the basis of a negative binomial model for testing differential expression of sequencing data 22 , we found 267,664 regions in the genome showing differential 5-hydroxymethylation modification between iPSCs and fibroblasts (false discovery rate (FDR): 0.01), denoted as differential 5-hydroxymethylated regions (DhMRs). Among them, 231,866 are hyperDhMRs (5hmC level is higher in iPSCs), and 35,798 are hypoDhMRs (5hmC level is lower in iPSCs; Fig. 2b ). The hyperDhMRs show a higher gain of 5hmC than the loss of 5hmC observed at hypoDhMRs (Fig. 2c) . The hyperDhMRs are distributed across all autosomes, but largely missing in sex chromosomes (Fig. 2d) . In particular, of the top 20,000 hyperDhMRs (ranked by adjusted P values), they have a higher probability (P < 0.0001) of being located in the telomere-proximal regions (Fig. 2e) , as shown by example of chromosome 1 and chromosome X (Fig. 2f) .
5hmC is bi-directionally correlated with DNA methylation changes and associated with pluripotency-related gene networks The analysis described above suggests a global hydroxymethylation change during reprogramming. 5hmC has been suggested to be linked with gene expression in ESCs and neurons 13, 14, [23] [24] [25] [26] . To assess the correlation between 5hmC modifications and gene expression changes during reprogramming, we stratified genes into 9 categories based on gene expression changes between iPSCs and fibroblasts (category 1: high expression in iPSCs, low expression in fibroblasts; category 2: medium expression in iPSCs, low expression in fibroblasts, and so on). We then quantified the amount of 5hmC around the transcription start site (TSS). As a result, those 9 categories can be clustered into 3 distinct patterns (Fig. 3a) . Of note, most genes expressed during reprogramming show a bimodal distribution with a depletion of 5hmC in TSSs, whereas genes that remain silenced after reprogramming show a peak in TSSs. Among the 3 clusters, cluster 1 has the lowest 5hmC levels in TSSs; cluster 3 has the highest levels of 5hmC in TSSs, but has the lowest 5hmC levels in gene bodies (Fig. 3b) .
We then examined the correlation between the absolute amount of transcripts and 5hmC enrichment. We noticed that hyperDhMRs tend to form a bimodal distribution associated with gene activity in iPSCs, with the lowest level similar to the level in fibroblasts in TSS regions ( Fig. 3c and Supplementary Fig. S2 ). Transcription end site (TES) regions also show a bimodal distribution; the depletion is more pronounced in a narrower region centred on the TES ( Supplementary  Fig. S2 ). However, when compared with hypoDhMRs, hyperDhMRs are more enriched in TSSs, exons and TESs ( Supplementary Fig. S3a ). We observed a significant negative correlation between the 5hmC level of regions surrounding TSSs (±200 base pairs (bp)) and gene expression levels in iPSCs ( Supplementary Fig. S3b) .
We also observe a bidirectional correlation between the 5hmC level and DNA methylation during the reprogramming process. Eighty percent of the partially methylated domains (PMDs), which exhibit lower levels of CG methylation in somatic cells than stem cells 27 , have increased 5hmC levels, with the rest having no 5hmC level change (Fig. 3d) . Interestingly, we also found that around 60% of stem cell hypoDMRs (lower CG methylation in stem cells) show increased 5hmC modification (Fig. 3b) . Collectively, our results suggest that increased hydroxymethylation occurs not only in loci with increased methylation but also in loci with decreased methylation during reprogramming.
On the basis of the results of bimodal distribution of 5hmC in TSSs and TESs, we then determined whether this distribution is associated with core pluripotency regulatory networks. We found that pluripotent master regulators, such as OCT3/4 and NANOG, bear this typical modification in iPSCs but not in fibroblasts (Fig. 3e) . We further investigated the relation between 5hmC and key pluripotencyfactor-binding sites 27 . We found a more than 8-fold higher than expected overlap between 5hmC-enriched regions and OCT4-and KLF4-binding sites, with a weak association with NANOG-and SOX2-binding sites (Fig. 3f) . Our results suggest that OCT4 and KLF4 regulatory networks may require 5hmC to regulate pluripotency during reprogramming. Furthermore, gene ontology analysis shows that genes acquiring most 5hmC are involved in stem cell differentiation and the patterning process (Fig. 3g) , suggesting that 5hmC levels in stem cells are highly correlated with pluripotency.
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Sequence preferences of 5hmC modification during reprogramming
We compared the CG, CH (CA, CT, CC) and CHG preference of hyperDhMRs and hypoDhMRs. HyperDhMRs tend to be located at higher C-and G-enriched regions, as well as CHG-and CH-enriched regions, whereas hypoDhMRs have the same level as the genome background (Fig. 3h) . Previous observations suggest that 5hmC modification is related to CpG density 24, 28 . We find that in iPSCs, the low-CpG-content group of CpG islands tend to have more 5hmC modifications ( Supplementary Fig. S3c ), which is consistent with the observation that DNA methylation occurs more frequently in CpG islands with a low CpG content 29 . Furthermore, 5hmC modifications acquired during reprogramming tend to occur within the unique sequence in which the methylation is evolutionarily less conserved 30 ( Supplementary Fig. S3d-f ).
Aberrant 5hmC reprogramming hotspots cluster in telomere-proximal regions
Reprogramming of somatic cells to a pluripotent state requires complete reversion of the somatic epigenome into the pluripotent epigenome, which is an ESC-like-state. iPSCs retain some type of somatic memory from their previous identity [31] [32] [33] . We further determined the genome-wide 5hmC modification differences between iPSCs and ESCs, aiming to understand whether 5hmC modifications underlie the differences between hESCs and iPSCs. To reduce the biases of tissue origins, we used 9 iPSCs derived from different origins, 6 of which are from fibroblasts as mentioned earlier, 2 are derived from peripheral blood cells, and 1 is derived from human exfoliated deciduous teeth cells (SHED).
In general, global DNA hydroxymethylation patterns are very similar between iPSCs and ESCs (Fig. 4a) . A comprehensive analysis of 372,423 5hmC-enriched regions between 4 hESC and 9 iPSC lines led to the identification of 113 iPSC-ESC DhMRs that were differentially hydroxymethylated in at least one iPSC or ESC line (FDR < 0.01), as shown for the SIGLEC6 and SIGLEC12 locus in Fig. 5a . Surprisingly, these regions are not randomly located across the genome; instead, they tend to cluster at the telomere-proximal regions, in particular, at chromosomes 3, 7, 8, 12 and 20 (Fig. 4b) .
In contrast to the symmetric pattern of DMRs between iPSCs and ESCs (ref. 17) , 105 of the 113 iPSC-ESC DhMRs are hypohydroxymethylated, with 5hmC levels similar to their respective progenitor blood cells or fibroblasts (Fig. 4c,d ). Of these DhMRs, the 5hmC patterns are more variable when compared with hESCs (Fig. 4d) . Unsupervised hierarchical clustering using the top 1,000 most variable 5hmC-modified regions among all samples could not distinguish hESCs from hiPSCs, suggesting that the variability among iPSCs is not due to different levels of pluripotency, and the 5hmC deviation of iPSCs is not a key determinant to distinguish hESCs from iPSCs (Fig. 4e) . Copy-number variation (CNV) has been reported to contribute to the variations of iPSCs (refs 34,35) . As DhMRs cluster at subtelomeric regions and show depletion of hydroxymethylation, we further examined whether the DhMRs were simply due to genetic variation, such as CNV, instead of real aberrant 5hmC epigenetic modification. To this end, we used a high-density comparative genomic hybridization (aCGH) array to examine 3 iPSCs and 2 hESCs. Array CGH yields an average of 70 CNVs on autosomes, none of which is overlapping with the iPSC-ESC DhMRs we identified ( Supplementary Fig. S4 ). Therefore, iPSC-ESC DhMRs are caused by aberrant epigenetic modification.
Concordance of large-scale 5hmC hotspots and iPSC-ESC non-CG DMRs
Our results suggest that iPSC-ESC DhMRs tend to cluster at telomereproximal regions, forming aberrant reprogramming hotspots. To better define these large-scale regions, we developed a statistical method to identify potential large-scale aberrant reprogramming hotspots. An aberrant reprogramming hotspot is defined as a genomic region satisfying the following conditions: large variability of 5hmC levels among iPSCs; the average 5hmC difference between iPSCs and ESCs is statistically significant, and longer than 100 kb. Twenty large-scale regions were identified. Among them, 19 are hypoDhMRs, all of which have the same epigenetic status as their parent cells, pointing to a somatic memory during reprogramming, and 1 is hyperDhMRs (Table 1) .
We then compared DhMRs with the DMRs identified previously using whole-genome single-base bisulphite sequencing, which would not be able to distinguish 5mC from 5hmC (ref. 17) . Of the total 113 DhMRs, only 5 overlap with 1,175 CG-DMRs (Fig. 5b) . Surprisingly, out of the 19 hypo large-scale hotspots, 84.2% overlap with the 24 mega-scale hypo-non-CG-DMRs, whereas the expected percentage is 1.6% based on permutation (Fig. 5c) . Figure 5d shows one of these regions, chr10: 132,010,001-133,270,001; 5mCH are depleted in iPSC but not hESC lines. Similarly, of the 9 total iPSCs, only iPSC-S1 and iPSC-S2 derived from blood bear similar levels of 5hmC compared to hESC counterparts. Of note, the variances from iPSCs are significantly larger than ESCs (Fig. 6a and Supplementary Fig. S5a,b) . None of the iPSC lines has all of the 19 hypo large-scale DhMRs restored to the same level as the 4 hESC lines (Fig. 6b) . This indicates that these large-scale regions tend to form aberrant reprogramming hotspots that were resistant to reprogramming. We did not observe a statistically significant (P = 0.54) correlation between passage number of iPSCs and the number of aberrant hotspots ( Supplementary Fig.  S5c ), implying that passage number may not be a key determinant of hotspot number in each iPSC line.
The aberrant 5hmC reprogramming hotspots we identified may also explain the transcription level variability in iPSCs. Notably, some of the genes, such as TCERG1L and FAM19A (Table 1) , have been reported to be expressed at a significantly lower level in many but not all iPSCs as compared with ESCs (refs 36,37).
Base-resolution 5hmC analyses reveal large-scale hotspots are mainly caused by aberrant CG hydroxymethylation
The observed extremely high concordance between hypo large-scale DhMRs and non-CG-DMRs is surprising, and might indicate that of the previously identified aberrant 5mCH hotspot regions, a significant portion of CH consists of 5hmC; alternatively, these regions could contain both non-CG (mC) and CG (hmC) aberrant modification. Most 5hmC in ESCs is found at CG sites 38 . In addition, 5hmC quantification by Tet-assisted-bisulphite sequencing (TAB-seq) and the chemical capture approach is well correlated both genome-wide and within the 20 large-scale hotspot regions ( Supplementary Fig. S6a,b) . Therefore, it is very likely that the aberrant 5hmC is caused by CG modification.
To investigate this possibility experimentally, we applied TAB-seq, which can detect hydroxymethylation status at base resolution, to 2 hESC and 4 iPSC lines. We performed base-resolution analysis level to ESCs; red indicates a lower 5hmC level than ESCs. 5hmC levels were determined by counting 5hmC Capture-seq reads within each hypo large-scale DhMR for each cell line. A lower 5hmC level in iPSCs was determined by the criterion that 5hmC levels were less than 2 s.d. from the mean among ESCs; if levels were within 2 s.d., the region was considered as having a similar 5hmC level. of 5hmC in 3 randomly chosen large-scale regions, chr10, chr18, chr22, and amplified 5hmC-enriched regions by PCR (Fig. 7a and Supplementary Tables S6 and S7). We then subjected them to deep sequencing. Deep sequencing of PCR amplicons after traditional bisulphite conversion confirmed that there is epigenetic variation in non-CG sites but not CG sites (Fig. 7b,d) . Consistent with the results obtained by the capture method, we observed similar 5hmC variations in iPSCs (Fig. 7c and Supplementary Fig. S6c,d) . Importantly, this incomplete hydroxymethylation is caused by CG modification, but not CH modification (Fig. 7c and Supplementary Fig. S6c,d ). For example, in the chr10 hotspot, iPSC-B22 and -B23 show incomplete 5hmC in CG dinucleotides, but not in CH dinucleotides (Fig. 7e) . Therefore, our results suggest the coexistence of aberrant non-CG methylation and CG aberrant hydroxymethylation in subtelomeric hotspots (Fig. 7f) . The concordance of aberrant CG hydroxymethylation with those aberrant CH large-scale regions suggests that there might be crosstalk between the epigenetic pathway that regulates hydroxymethylation and the pathway that regulates CH methylation; this crosstalk may behave more stochastically in those subtelomeric regions.
DISCUSSION
Our study suggests that the significant increase of 5hmC during reprogramming is mainly due to the activation of the TET1 protein in human iPSCs, which is in contrast to the previous observations that both Tet1 and Tet2 are upregulated in mouse iPSCs. Mouse ESCs are different from hESCs in many aspects, such as X-chromosome inactivation status in female lines 39 . From a cell-signalling perspective, human pluripotency (primed pluripotency) depends mainly on FGF and activin-nodal signalling pathways, whereas mouse pluripotency (naive/ground-state pluripotency) is maintained by LIF-STAT pathways. The difference between human and mouse TET family proteins involved in reprogramming may be caused by FGF signalling selection of a subpopulation of hiPSCs. Several studies of generating naive human iPSCs under LIF signalling have been reported 40, 41 . Thus, it is possible that TET1 and TET2 have distinct roles in regulating pluripotency, with TET2 being involved in naive pluripotency and TET1 functioning in primed pluripotency. On the other hand, it is possible that TET1-mediated 5hmC modification is unique in humans regardless of different pluripotent stages. As TET1/2 is dispensable for maintaining the pluripotency of stem cells, and their loss is compatible with embryonic and postnatal development 42 , it is likely that TET2 expression is not under positive selection for stem cell functions during evolution, and is thus eventually silenced in human pluripotent stages.
Reprogramming induces a remarkable epigenomic reconfiguration throughout the somatic cell genome. Recently, it was shown that TET1 and TET2, in synergy with NANOG, enhance the efficiency of mouse iPSC reprogramming 43 . Here we show that TET1-mediated hydroxymethylation change is critical for optimal human iPSC reprogramming. We further show that TET1-mediated 5hmC modification affects only the reprogramming efficiency, but does not alter the essential pluripotency in human stem cells. The pathways involving TET1 regulation largely remain unknown. It would be interesting to determine whether the known epigenetic factors such as DOT1L, Kdm2b and so on 44, 45 that are negative and positive modulators for reprogramming are linked to TET1-regulated hydroxymethylation modification.
Human iPSCs hold great promise for regenerative medicine and for establishing models of specific diseases. iPSCs and ESCs are known to share key features of pluripotency, including the expression of pluripotency markers, teratoma formation, cell morphology, the ability to differentiate into germ layers, and tetraploid complementation 46 . Two models depict the equivalence, or lack thereof, between iPSCs and ESCs. One model posits that there may be small but consistent differences between ESCs and iPSCs, as suggested previously 36, 47 ; the other model states that iPSCs and ESCs should be treated as two partially overlapping groups that share unique features. In this second model, single iPSC lines cannot be distinguished from ESC lines, although iPSCs show more epigenetic variance. Mounting evidence supports the latter model 16, 17, 32 . Therefore, each iPSC may represent a unique epigenetic status with variable differentiation potential. The cause and degree of variation remain to be determined. Our study integrates the 5hmC epigenomic mark into the investigation of ESC-iPSC equivalence. We find that 5hmC occurs extensively in iPSCs at levels similar to ESCs, and there are no consistent 5hmC markers that can distinguish iPSCs from hESCs; however, we identified 20 regions in iPSCs that tend to form large-scale (100 kb-1.3 Mb) aberrant reprogramming hotspots, supporting the present consensus that iPSCs are more epigenetically variable than ESCs. Remarkably, these regions with 5hmC variations tend to cluster in telomere-proximal regions. The close proximity of the hotspots to telomeres indicates there may be a distinct cellular process that could impede the reprogramming process.
Almost none of the DhMRs overlap with CG-DMRs, suggesting that CG-DMRs identified previously are primarily caused by DNA methylation. DNA methylation in non-CG contexts is abundant in pluripotent stem cells (mCHG and mCHH, where H = A, C or T), comprising almost 25% of all cytosines at which DNA methylation is identified. Strikingly, ∼80% of large-scale iPSC-ESC DhMR regions coincide with previously reported non-CG DNA methylation aberrant hotspots 17 . Reciprocally, ∼50% of non-CG DMRs overlaps with our identified DhMRs. It was reported that non-CG DMRs also occur in the peri-centromeric zones. Notably, these peri-centromeric regions contain a low level of 5hmC (stem cells have similar levels of 5hmC as fibroblasts), suggesting that cells do not need to establish 5hmC in these regions during reprogramming (Supplementary Fig. S7 ). Thus, the concordance occurs mainly at telomere-proximal regions. By applying TAB-seq, we show that incomplete hydroxymethylation occurs predominantly at CG sites, but not CH sites, suggesting the coexistence of aberrant non-CG methylation and aberrant CG hydroxymethylation in these regions. During reprogramming, both CH methylation and hydroxymethylation need to be established de novo from the somatic epigenome. It is known that non-CG cytosine methylation is exclusively catalysed by Dnmt3a and Dnmt3b (ref. 48) . The concordance suggests that there might be crosstalk between epigenetics pathways that regulate the activities of Tet and DNMT3, which may behave more stochastically in those subtelomeric regions.
Our results indicate that TET1-mediated 5hmC modification contributes to both the human iPSC reprogramming process and differences between iPSCs and hESCs. In particular, we identified 20 large-scale aberrant hotspots, suggesting that iPSCs are more epigenetically variable than ESCs in terms of 5hmC modification. Our data suggest that, when studying aberrant epigenetic reprogramming events, as well as their functional consequences, at the DNA level, 5hmC modification merits particular consideration, in addition to 5mC.
METHODS
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METHODS iPSC reprogramming and cell culturing. Human fibroblasts IMR90 and CRL2097 were obtained from ATCC, and GM0011 was obtained from Coriell Cell Repositories. The fibroblasts were cultured in DMEM medium containing 10% FBS, 1× non-essential amino acids, 1× glutamine and 1× penicillin/streptomycin. The H1 hESC and iPSC IMR90 were obtained from WiCell. HUES48, HUES49 and HUES53 were obtained from the Human Embryonic Stem Cell Collection at Harvard University. The cells were maintained in hESC/hiPSC standard medium (DMEM/F12, 20% KnockOut Serum Replacement, 1×MEM non-essential amino acids, 1× glutamine, 0.11 mM 2-mercaptoethanol, 10 ng ml −1 bFGF) on irradiated mouse embryonic fibroblast (MEF) feeders.
We focus on efficient reprogramming methods mainly by retrovirus, lentivirus and Sendai virus, all known to have distinct behaviours in establishing iPSCs (ref. 49) . As the stoichiometry of reprogramming factors can influence the epigenetic status of iPSCs (refs 47,50), we included the iPSCs reprogrammed by Yamanaka factors and Thomson factors either in polycistronic vectors or separate vectors.
For human iPSC-A2, -B22 and -B23 reprogramming, 2 × 10 5 fibroblasts were seeded in a well of a 6-well plate on day 1. On day 2, 10 µl of concentrated pMXs-hOCT4, hSOX2, hc-MYC and hKLF4 retrovirus were added to the cells in the presence of 6 µg ml −1 Polybrene. A second round of transduction was repeated on day 3. On day 7, the cells were reseeded in 10 cm dishes with irradiated MEF feeders. The potential hiPSC colonies were picked between days 18 and 25. The established iPSC cell lines were subsequently confirmed with alkaline phosphatase staining, immunofluorescence staining of pluripotent markers and the ability to differentiate into 3 germ layers. IPSC-AG2.3 and iPSC-RX35i were reprogrammed in a similar way except: iPSCAG2.3 was derived from fibroblasts transduced with a mixture of hOCT4, hSOX2, hNANOG and hLIN28 lentiviruses, and iPSC-RX35i were derived from fibroblasts by STEMCCA lentivirus. HiPSCS1 and hiPSCS2 lines were generated from peripheral blood mononuclear cells (PBMNs) of 2 healthy volunteers using Sendai virus (CytoTune-iPS kit; kindly provided by and property of DNAVEC), which are presumably free of transgene integration. To transduce cells, 4 separate Sendai viruses containing hOCT3/4, hSOX2, hKLF4 and c-MYC were used. Transduced cells were immediately plated onto a 12-well plate. Medium was replaced on day 1; on day 3 cells were trypsinized and passed onto 2 10-cm gelatin-coated culture dishes with irradiated MEFs. Cells were subsequently maintained in iPSC medium. iPSC colonies were manually isolated on the basis of morphology between day 14 and 30 post infection. hiPSCS3 was obtained by reprogramming stem cells from SHEDs using a STEMCCA lentiviral vector (a generous gift from G. Mostoslavasky, Boston University, USA) 51 . Briefly, pulp tissue from a primary upper central incisor was removed and digested in a solution of 1 mg ml −1 collagenase/dispase for 30 min at 37 • C. SHED cultures were maintained with alpha-MEM supplemented with 15% FBS, 2 mM glutamine, 100 U ml −1 penicillin and 100 µg ml −1 streptomycin until confluent. Cells (5 × 10 4 ) were infected with hSTEMCCA-loxP lentivirus for 24 h. Medium was then switched to iPSC medium and changed daily for 4 days. Cells were subcultured onto 10-cm gelatin-coated culture dishes seeded with irradiated MEFs. iPSC colonies were manually isolated between day 20-30 post infection.
RNA interference experiments. siRNAs targeting TET1, TET2 and TET3
were designed and validated by Dharmacons. TET1 siRNA sequences are: 5 -GAUAGGAGAUUAACAUUGG-3 ; 5 -GCUCAAACGAGGUCCAUUA-3 ; 5 -ACGAUUAGCUCCAAUUUAU-3 ; 5 -GACUCUAAUUGGUGUACAA-3 . The iPSCs were dissociated into single-cell suspensions by 0.5% trypsin-EDTA. Then 3 × 10 5 cells were plated on 6-well plates pre-coated with Matrigel in mTeSR1 medium in the presence of thiazovivin to increase single-cell survival rate. After 24 h, iPSCs were transfected with siRNA by RNAiMax according to the manufacturer's protocol. The final concentration for siRNA is 50 nM or 100 nM. At 48 h post transfection, the cells were evaluated by quantitative PCR with reverse transcription (qRT-PCR) or dot blot.
To assess TET1 function during reprogramming, CRL2097 fibroblasts were seeded at 1 × 10 5 cells per well of a 6-well plate. Cells were transduced with concentrated retrovirus containing Yamanaka factors in two consecutive days. On the first round of infections, cells were infected with an equal of titre lentivirus expressing either TET1 shRNA or GFP shRNA. Seven days later, cells were reseeded on puromycin-resistant MEF feeders in a 10 cm dish in hESC culture medium with puromycin (0.5 µg ml −1 ). Potential iPSC colonies were stained with alkaline phosphatase (Millipore) around 20 days after initial infection with Yamanaka factors. pLKO.1-shGFP (control) and pLKO.1-TET1 shRNA lentivirus were made according to standard procedures. The titre of concentrated virus was then determined by the Quick Titer Lentivirus Quantitation Kit (Cell Biolabs). TET1-75024(Sigma) shRNA sequence: 5 -CCGGCCCAGAAGATTTAGAATTGAT-CTCGAGATCAATTCTAAATCTTCTGGGTTTTTG-3 , pLKO.1-TET1-75026(Sigma) shRNA sequence: 5 -CCGGGCAGCTAATGAAGG-TCCAGAACTCGAGTTCTGGACCTTCATTAGCTGCTTTTTG-3 . pLKO.1-puro eGFP shRNA(Sigma) was used as control. 5hmC dot blot. DNA was spotted on an Amersham Hybond-N + membrane (GE Healthcare) and then fixed to the membrane by drying at 80 • C for 30 min. The membrane was then blocked with 5% BSA and incubated with a polyclonal antibody against 5hmC (1:5,000 dilution, Active Motif) as the primary antibody overnight at 4 • C. A horseradish-peroxidase-conjugated secondary antibody against rabbit (1:5,000 dilutions, Sigma) was used to incubate the membrane for 1 h at room temperature.
Immunofluorescence staining. Human iPSCs treated with either TET1 shRNA or control shRNA were plated onto coverslips that were pre-coated with Matrigel in mTeSR1 medium under puromycin selection (0.5 µg ml −1 ). Cells were fixed in 4% paraformaldehyde for 10 min. Then cells were permeabilized for 10 min with 0.25% Triton X-100. Cells were then incubated for 1 h with 4% donkey serum blocking buffer. Next, cells were incubated with primary antibody overnight at 4 • C. After washing with PBS 3 times for 5 min, secondary antibodies conjugated to Alexa Fluor-555 (Invitrogen) were used. The primary antibodies used were anti-NANOG (Cell Signaling, 3580s, 1:100), SOX2 (Santa Cruz, sc-20088, 1:100) and TRA-1-81 (Millipore, 90233, 1:100) Genomic DNA preparation and 5hmC capture. Before isolation of genomic DNA, hiPSCs/hESCs were treated with collagenase to detach from feeder cells, and transferred to Matrigel-coated culture plates in mTeSR1 medium (Stemcell Technologies) for at least 3 passages to eliminate the contamination of feeder cells. Genomic DNA was extracted and purified with the DNeasy Kit (Qiagen). Genomic DNA (20-30 µg) was sonicated to an average size of 200 bp by the Covaris sonicator. 5hmC labelling reactions were performed according to the previous protocol 11 with some modifications. Briefly, the UDP-6-N3-Glu transfer was carried out with 1× reaction buffer containing 50 mM HEPES (pH 7.9) and 25 mM MgCl 2 , 100 µM of UDP-6-N3-Glu and 2 µM of wild-type β-glucose transferase for 1 h at 37 • C. The labelled DNA was purified by the QIAquick PCR purification kit (Qiagen). Click chemistry was performed with the addition of 150 µM disulphide-biotin linker, and the mixture was incubated for 2 h at 37 • C. The biotin-labelled DNA samples were then captured by using Dynabeads MyOne Streptavidin C1 (Invitrogen) following the manufacturer's recommendations except eluted in dithiothreitol. Subsequently, the 5hmC-enriched DNA was purified by the MinElute PCR Purification Kit (Qiagen) and eluted with 12 µl elution buffer.
Quantitative RT-PCR. Total RNA was extracted using the RNeasy Kit (Qiagen).
Total RNA (2 µg) was converted to complementary DNA by using the iScript cDNA Synthesis Kit (Bio-Rad). The cDNA was then diluted by 1:200 and 8 µl of each diluted template was subjected to PCR amplification in a 20 µl volume mixed with Power SYBR Green Master Mix (Applied Biosystems). The PCR conditions were an initial 95 • C denaturation for 10 min followed by amplification cycles consisting of 95 • C for 10 s, 60 • C for 60 s, and 72 • C for 60 s for 40 cycles. For data analysis, the results were normalized with GAPDH signal. For iPSC colony analyses, cells were lysed and subjected to reverse transcription by using a Cells-to-Ct kit (Life Technologies) according to the manufacturer's protocol. Primer sequences are listed in Supplementary Table S5 .
Library preparation and Illumina sequencing for 5hmC captured DNA.
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identified using MACS (ref. 53 ) with the following parameters: effective genome size = 2.7 × 10 9 ; Tag size = 38 or 50; bandwidth = 250; P-value cutoff = 1.00 × 10 −5 with H1 genomic DNA input as a control.
DhMR identification.
To compare peaks between samples, the 5hmC-enriched regions in each sample were coalesced into a union window. We recounted the total aligned reads for each window, and then further normalized with each aligned total count. To call differential 5hmC-enrichment regions, the Bioconductor Deseq package was used for analysis, and a FDR of 0.01 was used for positive calling. When using iPSCs compared with original fibroblasts, we found a significant number of peaks, whereas using fibroblasts compared with a repeat experiment of fibroblasts yielded only background level of peaks, suggesting that we captured bona fide 5hmC modification in fibroblasts (Supplementary Table S4 ).
The large-scale aberrant reprogramming hotspots are defined as genomic regions satisfying the following conditions: the 5hmC levels are highly variable among iPSCs but relatively consistent among ESCs; the average difference of 5hmC levels between iPSCs and ESCs is large, and longer than 100 kb. To assess the variability of 5hmC levels, the whole genome was binned into 1 kb windows and the read counts within each window were obtained. The biological variation in each window was then calculated using a method of moment estimator (detailed in estimating 5hmC variations). We then smoothed the estimated variance by moving window average with 100 kb. The smoothed variances from iPSCs are significantly larger than from ESCs ( Supplementary Fig. S5a ). We then pooled the smoothed variations of iPSCs and ESCs, and used the 99th quantile as the threshold to detect variable 5hmC regions (VhMR) in iPSCs and ESCs. Thirty-three VhMRs were detected from iPSCs, and one VhMR was detected from ESCs. We then assessed the average 5hmC levels in these VhMRs. First the counts are normalized by total reads and average 5hmC levels are computed for iPSC and ESC. The average 5hmC levels are greater in ESCs for most VhMRs (Supplementary Fig. S5b) . The large-scale aberrant reprogramming hotspots are identified as genomic regions satisfying the following criteria: smoothed variances of iPSCs greater than the 99th quantile of the pooled variations; smoothed variances of ESCs smaller than the 50th quantile of the pooled variances; differences of smoothed averages between iPSCs and ESCs greater than the 95th quantile of all absolute differences; and minimum length greater than 100 kb. Detected regions closer than 50 kb are merged into one.
Estimating 5hmC variations.
We first obtained read counts in non-overlapping 1 kb windows. We denote the count for window i and sample j by X ij . X ij is assumed to follow a negative binomial distribution: X ij ∼ NB(s j θ ij ,φ i ). Here, θ ij is the true 5hmC level, s j is the library size and φ j is the dispersion parameter. The negative binomial is a γ-Poisson compound distribution. It assumes that the true 5hmC level θ ij follows a gamma distribution, and conditional on θ ij the observed counts follow a Poisson distribution. A negative binomial distribution accounts for over-dispersions (sample variance greater than sample mean) so it is often used for modelling sequencing data from biological replicates. The dispersion parameter ϕ j is the squared coefficient of variation of the true 5hmC level θ ij , and represents the variability among biological replicates. It can be shown that directly using the sample variances of normalized reads to estimate ϕ j will lead to erroneous results. Samples with larger library sizes will have smaller variance estimation. We designed the following moment estimator. First, define a new variable
; here µ ij is the expected value of θ ij . We first estimate µ ij asμ = ij X ij /S j , and then use the method of moment to obtain the estimates for ϕ j as Y ij /μ 2 ij − 1. Detailed proofs and derivations for the estimators are presented in a statistical paper 54 .
Tet-assisted bisulphite-based PCR amplicon sequencing. To investigate 5hmC distribution at a single-base resolution, hESC/ iPSC genomic DNA was subjected to glycosylation and catalysation by Tet as described previously 38 and the processed DNA was eluted in a ∼50 µl (500 ng) volume. The treated gDNA was bisulphite converted and eluted in 30 µl H 2 O. One microlitre of converted DNA was PCR amplified by using PfuTurbo Cx Hotstart DNA polymerase under the following conditions: 2.5 U polymerase, 5 µl 10× PfuTurbo Cx reaction buffer, 4 µl 2. Tables S6 and S7. The PCR amplicon was further purified by AMPure XP bead, and eluted in 50 µl H 2 O. The concentration was quantified with a Qubit High Sensitivity kit and then pooled together in an equal molar concentration for each sample. Then the mixed amplicons were subjected to library preparation and MiSeq deep sequencing. Briefly, samples were treated by end repair, A-tailing and the ligation of TruSeq adaptors containing compatible indexes by using NEBNext library preparation for the Illumina kit. Libraries were then quantified by KAPA SYBR FAST qPCR kits and pooled together with an equal molar concentration. MiSeq sequencing was performed as standard procedures recommended by Illumina: the concentration of pooled library used was 8 pM, and the run was initiated for 2 × 150 bases of SBS sequencing. Image analysis and base calling were performed with the standard Illumina pipeline. To call mC/5hmC status, the Bismark application was used.
Array CGH. Two micrograms of HUES48, HUES49, hiPSC-B22, hiPSC-B23 and hiPSC-RX35i DNA was co-hybridized with 2 µg H1 hESC reference DNA to 1×1 M Agilent SurePrint G3 Human Catalog oligonucleotide arrays (Agilent Technologies). The arrays span the entire genome with an oligonucleotide backbone spaced, on average, every 3 kb; the unique identifier (AMADID) for the design is 021529. Arrays were hybridized according to the manufacturer's instructions and scanned using the Agilent high-resolution C scanner (Agilent Technologies). Signal intensities were evaluated using Feature Extraction Version 9.5.1.1 software (Agilent Technologies) and analysed with Genomic Workbench 5.0 software (Agilent Technologies). To detect the maximum number of CNVs, we used a minimum absolute log ratio of 0.25 on at least 4 aberrant probes. To generate Supplementary Fig. S4 , the stringency was raised to 20 aberrant probes.
Genomic analysis. Microarray data on fibroblasts and iPSCs were obtained from a previous study 37 . The microarray data were normalized and analysed using Bioconductor's oligo 55 and siggenes packages within R (http://www.r-project.org/). The differentially expressed genes were called by SAM (significance analysis of microarrays) with corrected P-value <0.01.
RefSeq genes and CpG islands were defined on the basis of NCBI build 36/hg18 coordinates downloaded from the UCSC Genome Browser website. Core promoters were arbitrarily defined as 200 bp upstream and downstream of the TSS of RefSeq genes. Gene bodies are defined as the transcribed regions, from the start to the end of transcription sites for each RefSeq gene.
Association of DhMRs with genomic features was performed by overlapping defined sets of DhMRs with known genomic features obtained from UCSC Tables  for NCBI36/ 
